IPF: FROM PATHOGENESIS TO CURE

IPF: FROM PATHOGENESIS TO CURE
Palazzo delle Esposizioni
Rome, Italy - May 9-10, 2014
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic,
progressive fibrosing interstitial pneumonia of unknown cause, occurring
primarily in older adults, and limited to the lungs. It is characterized by
progressive worsening of dyspnea and lung function and is associated with a poor
prognosis.
The pathogenesis of IPF is still unclear and a complex series of pathological
events, many of which shared by other forms of pulmonary and systemic
idiopathic fibrosing disorders, have been shown to be involved in the development
of the typical Usual Interstitial Pneumonia (UIP) pulmonary lesions. Among them,
increased local production of reactive oxygen species, abnormal wound healing in
response to multiple microscopic injury, epithelial activation and hyperplasia,
presence of cellular de-differentiation and epithelial to mesenchymal transition,
imbalance in angiogenetic/angiostatic process, unusual proliferation of
mesenchymal cells with matrix deposition, disruption of coagulation pathway and
increase of capillary permeability.
On the research side, a growing number of studies have been aimed at the
identification of the susceptibility gene(s) or the environmental exposures that
could drive the pathogenic process of IPF. On the other hand, several controlled
clinical trials have been carried out and new effective agents are -or will be soonavailable for the treatment of IPF affected patients. In addition, considerable
efforts have been made by scientific societies and associations to improve upon
diagnostic and treatment standards for IPF patients and a simpler approach to the
diagnosis have emerged from these efforts. Most importantly, interest in IPF basic
and clinical research alike is continuously growing.
The purpose of this meeting is to provide an update on recent advances in the field
of the basic and clinical science of IPF. The most recent advancements in the
understanding of the biological processes responsible for IPF pathogenesis will be
critically reviewed and the most recent criteria for diagnosing and treating the
disease, both in research and real life settings, will be discussed.
PRELIMINARY PROGRAM
Friday May 9, 2014
09:30
Welcome
G. Novelli, Rector University of Roma “Tor Vergata”
Introduction
C. Saltini
SESSION 1
IDIOPATHIC FIBROSING DISORDERS-1
Chairs: F. Pallone, F. Pasqua
10:00
IgG4 related Disease - P. Graziano, San Giovanni Rotondo
10:30
Sarcoidosis - W. P. Drake, Nashville (TN, USA)
11:00
Pulmonary alveolar proteinosis - M. Luisetti, Pavia
11.30
Friedreich's ataxia - R. Testi, Roma
12:00
Coffee Break
SESSION 2
PATHOGENESIS OF IPF: INSIGHTS AND PROSPECTIVES
Chairs: R. Antonelli, F.Sangiuolo
12:30
13:00
Familial Interstitial Pneumonia - P. Rottoli, Siena
Mucin genes - D. Schwartz, Aurora (CO, USA)
13:30
Lunch
SESSION 3
VASCULAR ABNORMALITIES IN PULMONARY FIBROSIS
Chairs: M. Confalonieri, G. Mazzarella
14.30
15:00
15:30
Vascular abnormalities in smokers and COPD - JA. Barberà, Barcelona
Alveolar iron in IIPs: hemorrhage or inhalation? - E. Puxeddu, Roma
A common signaling pathway drives fibrosis in lung and skin - V. E.
Avvedimento, Napoli
16:00
Coffee Break
SESSION 4
IDIOPATHIC FIBROSING DISORDERS-2
Chairs: A. Orlandi, C. Mereu
16.30
Lung fibrosing damage - C. Saltini, Roma
17:00
Asbestosis - A. Ghio, Chapel Hill (NC, USA)
17:30
Hereditary hemochromatosis gene related diseases - E. Corradini,
Modena
Saturday May 10, 2014
SESSION 5
FROM GUIDELINES TO PATIENT MANAGEMENT: INTERACTIVE SESSION
Chairs: C. Agostini, G. Farinelli
Introduction
09:00
Radiologically confident IPF, real life - M. Zompatori, Bologna
Ground Round - MDD presentation: the possible/inconsistent IPF
09:30
Histological patterns - M. Chilosi, Verona
10:00
The clinical picture - V. Poletti, Forlì
10:30
Coffee Break
LECTURE
Chair: L. Palombi
11:00
Guidelines implementation: National, European, International? - D.
Valeyre, Paris (F)
SESSION 6
EVIDENCE BASED TREATMENT
Chairs: C. Albera, F. De Michele
11:30
12:00
From Ifigenia to Panther - F. J. Martinez, Ann Arbor (MI, USA)
Pirfenidone post-marketing studies – C. Vancheri, Catania
12:30
PH in IPF what to do: ERA, PDE5 inhibitors or palliation? - S. A. Harari,
Milano
13:00
Nintedamib rationale and clinical prospective - L.Richeldi, Southampton
(UK)
13:30
Closing remarks
CHAIRMEN
C. Saltini, Roma
V. Poletti, Forlì
L. Richeldi, Southampton UK
SCIENTIFIC COMMITTEE
C. Saltini, Roma
E. Puxeddu, Roma
G. Pezzuto, Roma
CONFERENCE VENUE
Palazzo delle Esposizioni
Via Milano, 9 – Roma
CONTINUING MEDICAL EDUCAZION
Continuing Medical Education (CME) accreditation will be available
for only Italian medical specialist.
The event has been insert in the Continuing Medical Education Planning AIPO
2014
Provider 442
ORGANIZING SECRETARIAT
Via A. Da Recanate, 2 - 20124 – MILANO
Tel. +39 02 36590350 - Fax +39 02 67382337
[email protected]
www.aiporicerche.it
www.aiponet.it

Download Report